Equities

Tivic Health Systems Inc

  • Add to watchlist
  • Add to portfolio
  • Add an alert
TIVC:NAQ

Tivic Health Systems Inc

Actions
Health CareMedical Equipment and Services
  • Price (USD)0.7915
  • Today's Change-0.019 / -2.28%
  • Shares traded45.78k
  • 1 Year change-85.68%
  • Beta2.0053
Data delayed at least 15 minutes, as of Mar 03 2026 20:59 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Tivic Health Systems, Inc. is a diversified therapeutics company, with complementary bioelectronic and biologic product candidates in its clinical pipeline. It harnesses the power of the immune and autonomic nervous systems to fight disease and restore health. It takes a multi-pronged approach to treating diseases caused by immune dysregulation and dysautonomia. The complement of bioelectronic and biologic medicines allows it to target disorders and disease via both neural pathways and molecular approaches. Its commercial product, ClearUP, is clinically proven to treat sinus pain and pressure. ClearUP is available through online retailers and commercial distributors. It also has worldwide exclusive license rights to the late-stage Toll-like Receptor 5 (TLR5) agonist Entolimod for the treatment of acute radiation syndrome (ARS). In addition, it has an exclusive option to license five additional indications and clinical use cases for Entolimod and its derivative, Entalasta.

  • Revenue in USD (TTM)482.00k
  • Net income in USD-7.51m
  • Incorporated2021
  • Employees7.00
  • Location
    Tivic Health Systems Inc47685 Lakeview BlvdFREMONT 94538United StatesUSA
  • Phone+1 (302) 636-5400
  • Fax+1 (302) 636-5454
  • Websitehttps://tivichealth.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Nu-Med Plus Inc0.00-54.13k1.28m2.00---------0.0006-0.00060.00-0.00310.00----0.00-910.51-451.95---------------8.61--------45.55------
STRATA Skin Sciences Inc30.98m-11.04m1.32m106.00--0.9022--0.0428-2.62-2.627.290.24940.87364.517.80292,264.20-31.13-14.64-52.77-21.5157.7659.75-35.64-21.510.746-4.020.921--0.61161.226.87---10.13--
Profusa Inc0.00-39.09m1.33m0.00---------278.73-278.730.00-61.050.00-------599.88-----------------14.56---------849.77------
Leafbuyer Technologies Inc5.08m49.72k1.40m12.0028.57----0.27570.00050.00050.0508-0.0155.27--74.98423,414.205.16-44.28----44.4937.830.9786-21.61--1.05----15.5420.68136.74-27.51----
Escalon Medical Corp12.31m-279.31k1.82m39.00--1.61--0.1476-0.0464-0.04641.350.23912.604.266.40315,666.90-5.291.53-10.773.4843.8743.87-2.030.70261.06-11.330.1195--0.53955.09115.88---42.12--
Agape ATP Corp1.48m-2.71m1.89m16.00--0.0828--1.27-14.97-14.972.6122.830.104713.9960.1492,806.88-19.46-34.76-21.27-44.4452.6869.19-185.74-92.8616.18--0.0056---7.57---17.53------
Tivic Health Systems Inc482.00k-7.51m2.05m7.00--0.2409--4.24-9.87-9.870.59143.360.10022.0734.4368,857.14-156.00-118.40-178.18-148.80-58.095.50-1,557.26-610.995.86--0.00---33.6713.1831.40------
Work Medical Technology Group Ltd9.85m-1.07m2.05m238.00--0.0056--0.2083-240.65-240.653,397.15214.44------41,393.78--1.52--4.5623.8322.30-12.162.521.50-7.750.23190.00-14.41-28.4569.28---39.54--
ENvue Medical Inc2.69m-5.21m2.15m15.00--0.0471--0.8025-83.93-83.937.4642.000.09090.83646.45179,000.00-25.01-97.63-32.90-149.1830.0253.04-275.12-397.830.6675--0.0669--12.0537.000.1617------
Zynex Inc108.20m-73.96m2.16m1.00k------0.0199-2.43-2.433.49-1.341.262.207.64108,202.00-86.3110.48-203.5512.4271.9079.57-68.357.510.3174-12.223.19--4.3633.44-69.24-20.6129.29--
Aethlon Medical Inc0.00-11.52m2.46m9.00--0.2711-----49.09-49.090.006.900.00----0.00-158.03-86.44-199.49-98.06-------3,662.04----0.00-------9.67------
Encision Inc6.30m-380.94k2.53m22.00--1.36--0.4019-0.0284-0.02840.50570.11051.662.277.98286,353.60-10.05-3.17-14.19-4.4052.6451.47-6.05-2.010.9127-5.690.1094---0.464-3.0968.17--8.09--
Catheter Precision Inc730.00k-22.19m2.64m22.00--0.3837--3.61-37.38-37.380.93714.120.0281.646.3533,181.82-66.93-128.03-78.29-160.1292.60-242.70-2,393.84-15,268.880.4569-66.840.0449---4.98-19.8969.45---24.21--
Nuwellis Inc8.17m-16.56m2.79m38.00--0.5204--0.3418-107.66-107.6626.642.871.111.656.71214,947.40-225.22-87.78-390.32-108.5359.0757.73-202.83-195.831.42-1.050.00---1.409.6653.05---34.30--
Data as of Mar 03 2026. Currency figures normalised to Tivic Health Systems Inc's reporting currency: US Dollar USD

Institutional shareholders

8.79%Per cent of shares held by top holders
HolderShares% Held
Avenue Capital Management II LPas of 30 Sep 2025101.64k4.02%
Marex Financialas of 31 Dec 202540.94k1.62%
Marex Prime Services Ltd.as of 30 Sep 202538.39k1.52%
UBS Securities LLCas of 31 Dec 202519.66k0.78%
G1 Execution Services LLCas of 31 Dec 202514.64k0.58%
Citigroup Global Markets, Inc. (Investment Management)as of 31 Dec 20255.00k0.20%
Tower Research Capital LLCas of 31 Dec 20251.65k0.07%
SBI Securities Co., Ltd.as of 31 Dec 202516.000.00%
Bank of America, NA (Private Banking)as of 31 Dec 202513.000.00%
DRW Securities LLCas of 31 Dec 20250.000.00%
More ▼
Data from 30 Sep 2025 - 31 Dec 2025Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.